StreetInsider.com News Articles

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Fri, 29 Aug 2025 01:15:00 -0500

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies
Data include an open-label extension study describing the long-term safety of FINTEPLA^®^▼ (fenfluramine)^{^[1]} and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome^[2]
Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors^[3],[4]
Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers^[5],[6],[7]

BRUSSELS, Aug. 29, 2025 /PRNewswire/ --